MedTrace Logo

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

NCT06989359 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-04-22

No results posted yet for this study

Summary

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.

Conditions

  • IgAN
  • C3G
  • Complement-mediated Kidney Disease
  • IgA Nephropathy (IgAN)
  • IC-MPGN

Interventions

DRUG

ADX-038 Dose Level 2

siRNA duplex oligonucleotide

DRUG

ADX-038 Dose Level 1

siRNA duplex oligonucleotide

Sponsors & Collaborators

  • ADARx Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Aditya Patel, MD · ADARx Pharmaceuticals, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-28
Primary Completion
2028-12-31
Completion
2029-06-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Hong Kong
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06989359 on ClinicalTrials.gov